Personal CFO Solutions LLC Invests $250,000 in DexCom, Inc. (NASDAQ:DXCM)

Personal CFO Solutions LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,212 shares of the medical device company’s stock, valued at approximately $250,000.

Other institutional investors have also modified their holdings of the company. Versant Capital Management Inc purchased a new position in shares of DexCom during the 4th quarter worth $25,000. Private Trust Co. NA raised its holdings in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares during the period. Larson Financial Group LLC raised its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after acquiring an additional 137 shares during the period. Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth $38,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of DexCom during the 4th quarter worth $49,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DXCM shares. Canaccord Genuity Group lifted their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research report on Saturday. Finally, Citigroup raised their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

Insider Activity

In other news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Performance

NASDAQ DXCM opened at $70.72 on Tuesday. The stock has a 50-day moving average of $84.68 and a two-hundred day moving average of $77.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company has a market cap of $27.64 billion, a P/E ratio of 49.45, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.